Company Filing History:
Years Active: 1993
Title: Barry G Arnason: Innovator in Autoimmune Disease Treatment
Introduction
Barry G Arnason is a notable inventor based in Chicago, IL (US). He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. His innovative approach has led to advancements that may improve the quality of life for many patients.
Latest Patents
Arnason holds a patent for the use of .beta.-adrenergic agonists to treat patients with demyelinating conditions. The present invention discloses improved methods for the treatment of autoimmune diseases using .beta.-adrenergic agonists, particularly .beta..sub.2 -adrenergic agonists. His research demonstrated that treatment with the .beta..sub.2 -adrenergic agonist terbutaline significantly suppressed clinical disease in animal models. A Phase I safety treatment trial with terbutaline was conducted in multiple sclerosis (MS) patients, where twenty-four patients were treated for four weeks. Remarkably, no obvious side effects were observed during the trial. At the end of the four weeks, 15 of the 24 patients showed improvement on the neurologic rating scale, and 17 patients reported subjective improvement.
Career Highlights
Throughout his career, Arnason has worked with various organizations that focus on medical research and development. Notable companies include Arch Development Corporation and Iterative Therapeutics, Inc. His work has been instrumental in advancing therapeutic options for patients suffering from autoimmune diseases.
Collaborations
Arnason has collaborated with esteemed colleagues in his field, including Ewa E Chelmicka-Schorr and Anthony Thomas Reder. These collaborations have further enriched his research and contributed to the success of his innovative treatments.
Conclusion
Barry G Arnason's contributions to the treatment of autoimmune diseases through his patent on .beta.-adrenergic agonists highlight his role as a significant innovator in the medical field. His work continues to inspire advancements that may benefit countless patients in the future.